KEYTRUDA 25 mg/mL concentrate for solution for infusion., Darleukin, Fibromun
PH-ICKPD1-02/21
Phase 2 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion., Darleukin, Fibromun for Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy is a Phase 2 program (small_molecule) at Philogen S.p.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Philogen S.p.A.
- Indication
- Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active